Tant de raisons d’utiliser le kit MB dans vos projets
Parce que des chiffres valent mieux que des mots
Un éventail d'applications
à votre disposition
Les écrits restent,
les paroles s'envolent
Imprégnez-vous des articles scientifiques rédigés par nos clients et partenaires, qui ont utilisé le kit CYTO dans leurs recherches et témoignent de son efficacité.
Cancer du poumon
Objectives Circulating tumour cells (CTCs) are reported to be predictive for prognosis and response to treatment in advanced lung cancer....
Adénocarcinome œsophagien
Introduction: Esophageal adenocarcinoma (EAC) often recurs systemically despite therapy with a curative aim. New diagnostic and therapeutic approaches are urgently...
Cancer de la prostate
Selecting a well-suited method for isolating/characterizing circulating tumor cells (CTCs) is challenging. Evaluating sensitive and specific markers for prostate cancer...
Cancer du sein
Background: Progression to stage IV disease remains the main cause of breast cancer-related deaths. Increasing knowledge on the hematogenous phase...
Cancer du sein
Circulating tumor cells have a strong potential as a quasi-non-invasive tool for setting up a precision medicine strategy for cancer...
Cancer colorectal
Circulating tumor cells (CTCs) detach from a primary tumor or its metastases and circulate in the bloodstream. The vast majority...
Biopsie liquide
Liquid biopsies represent a valid alternative to conventional tissue biopsies, offering a real time molecular picture of tumors in a...
Cancer de la prostate
Selecting a well-suited method for isolating/characterizing circulating tumor cells (CTCs) is challenging. Evaluating sensitive and specific markers for prostate cancer...
Cancer colorectal
Les mutations somatiques présentes dans les gènes RAS (KRAS et NRAS) sont largement associées à l’absence de réponse aux traitements...
Cancer du sein
A challenge for circulating tumor cell (CTC)-based diagnostics is the development of simple and inexpensive methods that reliably detect the...
Cancer colorectal
In colorectal cancer (CRC), KRAS mutations are a strong negative predictor for treatment with the EGFR-targeted antibodies cetuximab and panitumumab....
Preuve de concept
Background: Circulating tumor cells (CTCs) likely derive from clones in the primary tumor, suggesting that they can be used for...
Pour l'amélioration de la
prise en charge des patients
grâce à l'analyse des CTC
prise en charge des patients
grâce à l'analyse des CTC
